Research
Molecular
GLP-1 receptor agonists and dual incretin agonists provide clinically significant benefits in weight reduction, blood pressure modulation, lipid profile improvement, and cardiovascular risk mitigation.
Practitioners can consider GLP-1 receptor agonists and dual agonists as effective options for managing weight and cardiovascular health in patients with T2DM and obesity.
StrongSupportsmedium confidence
these agents demonstrate clinically significant benefits in weight reduction, blood pressure modulation, lipid profile improvement, and cardiovascular risk mitigation.
Why this rating
The review synthesizes peer-reviewed literature.
Source
Biochemical and Pharmacological Mechanisms of GLP-1 and Dual Agonists: Implications for Glycemic Control and Cardiovascular Risk Reduction — A Review
Akter Sraboni et al. · Journal of Biochemistry Pharmacology and Public Health · 2026
DOI 10.64907/xkmf.v4.i1.jbpph.1
review
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Molecular
- QRISK decreased markedly after weight loss from 18.9 ± 2.2% to 11.2 ± 1.6%, p < 0.0001.Strong
- Normalization of 10-year cardiovascular risk and heart age is possible after substantial dietary weight loss and remission of T2DM.Strong
- The Low-Fat Plus diet resulted in a greater reduction in total cholesterol compared to the Low-Fat diet, with changes of -0.46 mmol/L (-17.6 mg/dL) versus -0.24 mmol/L (-9.2 mg/dL) respectively (P = 0.01).Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →